MagnetisMM-7
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant
What will happen during the trial?
This study is being conducted in three different parts (or arms). The two arms in this study that are open for enrollment are Arms B and C. Arm A is no longer open for patient enrollment. In Arm B, participants will receive Lenalidomide as maintenance therapy, and in Arm C participants will receive Elranatamab as maintenance therapy.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 760 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody, GPRC5D
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1322
- NCT Identifier
- NCT05317416
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.